Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. contitrace

ContiTRACE SIGNED

Continuous Blood Glucose Monitoring and automated therapeutic closed loop medical device for Intensive Care Units

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ContiTRACE project word cloud

Explore the words cloud of the ContiTRACE project. It provides you a very rough idea of what is the project "ContiTRACE" about.

public    made    glucose    sasse    discomfort    lifecycle    manufacturers    300    aventis    minutes    automated    doctors    death    x10    decrease    samples    estimates    savings    private    consumables    elektronik    big    adjustments    companies    care    forecast    40    14    accesses    intensive    standardized    time    patented    patient    commercial    monitoring    max    2022    pharma    invasive    sanofi    pfizer    penetrate    roche    continuous    profits    twofold    newcomers    bgm    levels    risk    self    15    investment    optimize    irregular    comorbidities    50    distributors    fluctuations    5th    icu    workload    limited    proves    business    human    days    headcounts    blood    mortality    2026    careful    units    patients    company    medical    material    intermittent    sensors    manual    device    model    informed    icus    profil    regulatory    automatically    17    calibrating    increments    economic    return    players    caregivers    decisions    infusion    healthcare    safe    hospital    trace    minimising    ai    insulin    inefficient    glycaemic    infuse    physiological    contitrace    keep    powered    safety    diagnostica    costly    offline    sell    technique    body   

Project "ContiTRACE" data sheet

The following table provides information about the project.

Coordinator		 TRACE ANALYTICS GMBH 

Organization address
address: RICHARD WAGNER STRASSE 1-2
city: BRAUNSCHWEIG
postcode: 38106
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Germany [DE]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-12-01   to  2020-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    TRACE ANALYTICS GMBH DE (BRAUNSCHWEIG) coordinator 50˙000.00

Map

 Project objective

Intensive Care Units (ICUs) require careful monitoring of blood glucose levels and insulin infusion to keep patients within safe physiological levels. Fluctuations of blood glucose are directly related to an increased risk of death and comorbidities. However, blood glucose monitoring (BGM) is still made by intermittent and manual offline analysis of blood samples. This technique proves inefficient (need 17% caregivers time), costly (€300 per patient) and increments mortality in hospital ICUs by 40% due to irregular glucose level adjustments upon measurements. After 15 years of experience in developing glucose monitoring sensors, we at TRACE are taking on our next big step to penetrate the medical device sector with ContiTRACE: an AI powered automated non-invasive medical device for continuous BGM. Our patented ContiTRACE is able to measure glycaemic levels every 2 minutes (automatically) and automatically infuse insulin when needed. It is also capable of self-calibrating and has standardized body accesses, enhancing safety and minimising discomfort for the ICU patient. This will allow 1) caregivers to decrease their workload, 2) doctors to take informed decisions and 3) the healthcare system to optimize their limited human, economic and material resources by providing savings of more than 50% of BGM related cost. Our business model is twofold. We will sell the medical device (5 years lifecycle), and the consumables (max. 4 days duration per set) to private and public hospital ICUs. Our draft forecast (2022-2026) estimates profits of 14.4 M€ with a Return on Investment of 10.7 by the 5th commercial year allowing us to increase x10 our company headcounts in five commercial years. Although newcomers to the medical sector we have the support of key players among regulatory companies (Profil), manufacturers (Sasse Elektronik), pharma companies (Sanofi-Aventis, Pfizer and Roche) and distributors (Care Diagnostica) to take on the BGM challenge.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CONTITRACE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CONTITRACE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Colourganisms (2020)

Microbial production of custom-made, pure and sustainable anthocyanins

Read More  

Woodywood pickering (2019)

Bio-based (fully renewable) cost effective Polymer for new generation of ecological Coatings leveraging a disruptive innovation in the use of Pickering emulsion.

Read More  

Primavera (2018)

Primavera: immunobiotics for treating early stage Age-related Macular Degeneration (AMD)

Read More